This site uses third party services that need your consent.
Primary patient-derived cancer stem cell (GSC) lines have become a cornerstone of translational research in glioma. Unlike long-established immortalized cell lines, patient-derived GSCs preserve key genetic, epigenetic, and phenotypic features of the original tumor, including intratumoral heterogeneity and stem-like properties such as self-renewal and tumor initiation capacity.
These models more accurately reflect clinically relevant characteristics such as therapy resistance, invasive growth, and molecular subtype diversity. As a result, they provide a more predictive platform for testing novel targeted therapies, immunotherapies, and combination treatments before advancing to clinical trials.